XTNTHealthcare · Medical DevicesThe 2 Wall Street analysts covering Xtant Medical Holdings, Inc. hold a median 12-month price target of $1.05 — +223.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 83 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Xtant Medical Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (96): Reported profit is backed by cash, and the company is not expanding recklessly.
Growth (19): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on XTNT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +223.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 May 2026 | BTIG | Reiterates | Buy | — |
| 31 Mar 2026 | BTIG | Maintains | Buy | — |
| 11 Nov 2025 | BTIG | Maintains | Buy | — |
| 16 May 2024 | BTIG | Maintains | Buy | — |
| 5 Dec 2023 | BTIG | Initiates | Buy | — |
| 11 July 2023 | Craig-Hallum | Maintains | Buy | — |
| 26 Apr 2023 | Craig-Hallum | Initiates | Buy | — |
| 17 May 2019 | Maxim Group | Downgrade | Hold | — |
| 8 Dec 2016 | Maxim Group | Initiates | Buy | — |
| 30 Nov 2016 | Aegis Capital | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. XTNT appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 25% of US stocks
Cheaper than 85% of US stocks
Cheaper than 70% of US stocks
Cheaper than 93% of US stocks
Higher than 7% of US stocks
Higher than 13% of US stocks
Higher than 71% of US stocks
Higher than 22% of US stocks
Higher than 20% of US stocks
Higher than 29% of US stocks
Higher than 33% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Xtant Medical Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Xtant Medical Holdings held its Q2 2026 earnings call, the transcript of which was published by Seeking Alpha.
Why it matters — XTNT watchers would want to review the earnings call transcript for details on the company's financial performance and strategic outlook for the quarter.
Xtant Medical Holdings reported its financial and operating results for the second quarter ended June 30, 2026. The company also announced the launch of Trivium™ Shaped, an extension of its Trivium line of demineralized bone matrix allografts, and will host an investor conference call on August 11 at 8:30am ET.
Why it matters — XTNT watchers would care because the quarterly results and the new product launch provide an update on the company's recent financial performance and its product portfolio expansion.
Xtant Medical announced it will release its second quarter 2026 financial results before trading opens on August 11, 2026. The results cover the period ended June 30, 2026.
Why it matters — The release will provide investors and analysts with an update on Xtant's financial performance and operational results for the recent quarter.
Xtant Medical announced that CEO Sean Browne, CFO Scott Neils, and COO Mark Schallenberger will participate in the Canaccord Genuity 46th Annual Growth Conference, held August 11-13, 2026, in Boston. The company is a medical technology firm focused on surgical solutions for spinal and other orthopedic conditions.
Why it matters — Xtant's management will present the company to investors and industry participants at a major growth conference, offering potential visibility for the company.
The 2 Wall Street analysts covering Xtant Medical Holdings, Inc. have a median 12-month price target of $1.05, with estimates ranging from $0.6 to $1.5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering Xtant Medical Holdings, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Xtant Medical Holdings, Inc. 83 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Xtant Medical Holdings, Inc. ranks 83 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (96 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +223.2% from the last close, and Ticker Nerd's factor model ranks Xtant Medical Holdings, Inc. 83 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Xtant Medical Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XTNT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $0.6 to $1.5 over the next 12 months.
Xtant Medical Holdings, Inc. returned -48.4% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Xtant Medical Holdings Inc. is a leading company in the medical device sector, specializing in the development and distribution of regenerative medicine products and surgical implants.
The most recent item we track (Seeking Alpha, 11 Aug 2026): "Xtant Medical Holdings, Inc. (XTNT) Q2 2026 Earnings Call Transcript". Xtant Medical Holdings held its Q2 2026 earnings call, the transcript of which was published by Seeking Alpha.
Xtant Medical Holdings Inc. is a leading company in the medical device sector, specializing in the development and distribution of regenerative medicine products and surgical implants. The core purpose of the company is to improve patient outcomes through innovative solutions in orthopedic and neurological surgery. Xtant Medical’s product offerings include biologics and other advanced materials designed to support the healing and repair of tissue, primarily within the spine and broader orthopedics market. Their products are integral in the treatment of complex injuries and conditions, playing a crucial role in both surgical intervention and recovery processes. Based in the healthcare industry, Xtant Medical Holdings Inc. serves hospitals, surgical centers, and clinics, providing essential tools for managing patient care. In the financial market, Xtant's products and innovations position the company as a critical provider within the medical technology landscape, underlining its market presence and influence in advancing medical treatments.
CEO Mr. Sean E. Browne · 151 employees · United States · https://xtantmedical.com